NEWTOWN, Pa. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (CSE:HSM) (“HMT”, or the “Company”) announced today that its flagship PoNS™ technology would be tested in a double-blind, randomized, sham-controlled pilot efficacy study in volunteer human subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI). The PoNS™, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (TBI). The study is being conducted at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. HMT is developing a commercial version of the prototype PoNS™ device used in the trial.
Help employers find you! Check out all the jobs and post your resume.
